| scholarly article | Q13442814 |
| P2093 | author name string | Masato Fujisawa | |
| Hideaki Miyake | |||
| P2860 | cites work | The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy | Q24596735 |
| Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets | Q24629083 | ||
| Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis | Q24645292 | ||
| Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 | ||
| Cancer Incidence and Incidence Rates in Japan in 2005: Based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project | Q33685238 | ||
| Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications | Q33899708 | ||
| Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature | Q33993472 | ||
| Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy | Q34332665 | ||
| Decision curve analysis: a novel method for evaluating prediction models | Q34581068 | ||
| Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients | Q34687525 | ||
| PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. | Q34830787 | ||
| Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. | Q35739109 | ||
| Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy | Q35748251 | ||
| Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy | Q35751889 | ||
| Environmental, genetic, and molecular features of prostate cancer | Q35761690 | ||
| Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer | Q35783032 | ||
| Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic | Q36275522 | ||
| Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer | Q36307424 | ||
| When and how to use informatics tools in caring for urologic patients | Q36395152 | ||
| Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy | Q36439622 | ||
| Biochemical recurrence after localized treatment | Q36456470 | ||
| Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy | Q36458146 | ||
| Prostate-specific antigen in clinical practice | Q36720221 | ||
| Targeting cell cycle kinases for cancer therapy | Q36793881 | ||
| Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. | Q36836075 | ||
| External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. | Q37016132 | ||
| Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer | Q37024519 | ||
| Predictive models and prostate cancer | Q37079695 | ||
| Radical prostatectomy in the 21st century - the gold standard for localized and locally advanced prostate cancer | Q37188302 | ||
| The role of stress proteins in prostate cancer | Q37223453 | ||
| An updated catalog of prostate cancer predictive tools | Q37281541 | ||
| Molecular mechanisms of metastasis in prostate cancer | Q37339692 | ||
| Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. | Q37342007 | ||
| Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer | Q37460247 | ||
| Biomolecular markers of outcome prediction in prostate cancer. | Q37526794 | ||
| Is radical prostatectomy the "gold standard" for localized prostate cancer? | Q37654243 | ||
| Discovery of prostate cancer biomarkers by microarray gene expression profiling | Q37656262 | ||
| Chemosensitization of prostate cancer by modulating Bcl-2 family proteins | Q37713757 | ||
| Prostate-specific antigen testing and prostate cancer screening | Q37779624 | ||
| Prognostic factors for the development of biochemical recurrence after radical prostatectomy | Q37960019 | ||
| Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification | Q37966308 | ||
| Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report | Q38446418 | ||
| Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x | Q38452930 | ||
| Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy | Q38458031 | ||
| Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial | Q39518034 | ||
| Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens | Q39669878 | ||
| Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy | Q39724803 | ||
| Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. | Q40001031 | ||
| External validation of the updated Partin tables in a cohort of North American men. | Q40069634 | ||
| Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy | Q40351753 | ||
| External validation is necessary in prediction research: a clinical example | Q40549827 | ||
| Internal and external validation of predictive models: a simulation study of bias and precision in small samples | Q40556623 | ||
| Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer | Q40813169 | ||
| The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome | Q41004138 | ||
| Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer | Q41790088 | ||
| Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum | Q41862911 | ||
| Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates | Q42135518 | ||
| A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer | Q42522113 | ||
| Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy | Q42643294 | ||
| Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. | Q43467766 | ||
| Multi-institutional external validation of seminal vesicle invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007 Partin tables. | Q44263760 | ||
| A nomogram predicting metastatic progression after radical prostatectomy | Q44940107 | ||
| Predicting non-organ-confined prostate cancer in men diagnosed after 2000. | Q46604306 | ||
| Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy | Q46679248 | ||
| Trifecta outcomes after robotic-assisted laparoscopic prostatectomy | Q46815652 | ||
| The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer | Q47697130 | ||
| A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer | Q48030260 | ||
| Game relativity: how context influences strategic decision making | Q48457473 | ||
| Validation of the partin nomogram for prostate cancer in a national sample. | Q51799565 | ||
| Can nomograms be superior to other prediction tools? | Q51864212 | ||
| Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. | Q53552089 | ||
| Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. | Q53564658 | ||
| Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. | Q55067996 | ||
| Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition | Q56906348 | ||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 301-311 | |
| P577 | publication date | 2012-09-30 | |
| P1433 | published in | International Journal of Urology | Q15767019 |
| P1476 | title | Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches | |
| P478 | volume | 20 |
| Q39644934 | Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer. |
| Q87172622 | Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy |
| Q41236835 | Genome-wide detection of allelic genetic variation to predict biochemical recurrence after radical prostatectomy among prostate cancer patients using an exome SNP chip |
| Q31111207 | Logic Learning Machine and standard supervised methods for Hodgkin's lymphoma prognosis using gene expression data and clinical variables. |
| Q89243697 | MALAT1 silencing suppresses prostate cancer progression by upregulating miR-1 and downregulating KRAS |
| Q95262067 | Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer |
| Q38226242 | Molecular markers to guide primary radical treatment selection in localized prostate cancer |
| Q53474041 | Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: Results from a prospective single-center study. |
| Q41834435 | Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score |
| Q38207592 | Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. |
| Q46569706 | The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients |
| Q35195342 | miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer |
Search more.